Table 1.

Details of chemotherapy

BEACOPP (repeat course every 21 days)

(B) Bleomycin 10 U/m2 IV, day 7

(E) Etoposide 200 mg/m2 IV, days 0, 1, 2

(A) Doxorubicin 35 mg/m2 IV, day 0

(C) Cyclophosphamide 1200 mg/m2 IV, day 0

(O) Vincristine 2 mg/m2 (maximum 2 mg) IV push, day 7

(P) Prednisone 40 mg/m2 per day PO, divided into 2 doses, days 0-13

(P) Procarbazine 100 mg/m2 per day, days 0-6

G-CSF 5 μg/kg per day SC, starting day 8 and continuing until absolute neutrophil count was > 1000/μL

COPP/ABV (female rapid early responders, repeat course every 28 days)

(C) Cyclophosphamide 600 mg/m2 IV, day 0

(O) Vincristine 1.4 mg/m2 (no maximum dose) IV push, day 0

(P) Prednisone 40 mg/m2 per day PO, divided into 2 doses, days 0-13

(P) Procarbazine 100 mg/m2 per day, days 0-6

(A) Doxorubicin 35 mg/m2 IV, day 7

(B) Bleomycin 10 U/m2 IV, day 7

(V) Vinblastine 6 mg/m2 IV, day 7

ABVD (male rapid early responders, repeat course every 28 days)

(A) Doxorubicin 25 mg/m2 IV, days 0, 14

(B) Bleomycin 10 U/m2 IV, days 0, 14

(V) Vinblastine 6 mg/m2 IV, days 0, 14

(D) Dacarbazine 375 mg/m2 IV, days 0, 14

IV indicates intravenously; PO, orally; G-CSF, granulocyte colony-stimulating factor; and SC, subcutaneously.